ABSTRACT
Objective To investigate the effects of different concentration propofol target controlled infusion on postoperative cognitive function in patients undergoing coronary artery bypass grafting.Methods182 cases with coronary heart disease undergoing off-pump coronary artery bypass grafting were randomly divided into groupA and groupB from January 2014 to December 2016 in our hospital, 91cases in each group.GroupA were given a small dose propofol target controlled infusion anesthesia;groupB were given high dose propofol target controlled infusion anesthesia.The total dose of propofol induction and effect compartment concentration in the two groups were observed, and the Mini Mental State Examination(MMSE) in the two groups was evaluated preoperative, postoperative 24h, 48h, 72h.Concentration of S100β was determined at suture, postoperative 24h, 72h.ResultsThe total dose of propofol induction in the groupA was significantly lower than that in the groupB (P<0.05), effect compartment concentration between the two groups had no statistically significant difference.MMSE scores in the group A at postoperation 24h, 48h, were higher than those in the group B (P<0.05).Concentration of S100β in the group A was lower than those in the group B at suture, postoperative 24h, 72h.MMSE and concentration of S100β in the two groups were not statistically significant at post operation 72h.ConclusionLow dose propofol target controlled infusion can reduce postoperative cognitive dysfunction in patients undergoing coronary artery bypass grafting, which is worthy of clinical application.
ABSTRACT
OBJECTIVE:To observe the clinical efficacy and safety of ezetimibe combined with simvastatin in the treatment of membranous nephropathy complicated with hyperlipidemia. METHODS:90 patients with membranous nephropathy complicated with hyperlipidemia were randomly divided into observation group and control group,45 cases in each group. All patients received health guidance,low-fat diet,and the drugs without interfere with regulating lipid,hepatoprotective and lipid metabolism were for-bid. Control group was orally given 20 mg Simvastatin tablet,qd;observation group was additionally given 10 mg Ezetimibe tab-let,qd. They were treated for 8 weeks. Clinical efficacy was observed,lipid levels [total cholesterol(TC),triglyceride(TG),low density lipoprotein cholesterol (LDL-C),high density lipoprotein cholesterol (HDL-C)],aspartate aminotransferase (AST),ala-nine aminotransferase(ALT),urinary protein quatitation,creatine kinase(CK)before and 2,4,8 weeks after treatment,and the incidence of adverse reactions were compared. RESULTS:Total effective rates of membranous nephropathy and hyperlipidemia were 95.56% and 93.30% in observation group,which were significantly higher than 73.33% and 75.56% in control graup,with statistical significance (P0.05);after 8 weeks of treat-ment,TC level in observation group was significantly lower than control group,the differences were statistically significant (P0.05). And there was no significant difference in the incidence of adverse reactions between 2 groups(P>0.05). CONCLUSIONS:Ezetimibe shows similar clinical efficacy with simvastatin in the treatment of membranous nephropathy complicated with hyperlipidemia,it can effectively reduce TC level,with good safety.